Abstract 10312: Factor XIa Inhibitors for Secondary Prevention After Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack: A Bayesian Network Meta-Analysis
Faktor-XIa-Inhibitoren zur Sekundärprävention nach nicht-kardioembolischem ischämischem Schlaganfall oder Hochrisiko-TIA: Bayesische Netzwerk-Metaanalyse
Circulation · 02.11.2026 · 154 (Suppl_1)
DOI: 10.1161/circ.154.suppl_1.10312 ↗Auf einen Blick
Drei RCTs mit 16.255 Teilnehmenden verglichen Faktor-XIa-Inhibitoren mit Placebo. Für ischämische Endpunkte lagen Milvexian-Regime vorn, für Blutungssicherheit niedrigere Asundexian-Dosen.
Fragestellung
Wie wirksam und sicher sind verschiedene Faktor-XIa-Inhibitor-Regime bei Patient:innen nach nicht-kardioembolischem ischämischem Schlaganfall oder Hochrisiko-TIA?
Methode
Systematische Suche in Datenbanken und Studienregistern; bayesische random-effects Netzwerk-Metaanalyse von RCTs mit Hintergrund-Antiplättchentherapie; Einschluss innerhalb von 48-72 Stunden nach dem Indexereignis.
Ergebnisse
3 RCTs mit 16.255 Teilnehmenden. Für ischämischen Schlaganfall hatte Milvexian 100 mg BID die höchste Reduktionswahrscheinlichkeit (SUCRA 63,81), für TIA Milvexian 50 mg BID (SUCRA 69,92). Für schwere Blutungen lag Asundexian 20 mg OD vorn (SUCRA 69,10).
Einschränkungen
Die 95 %-CrIs waren breit und überlappten; die direkte und indirekte Evidenz war insgesamt konsistent.
Schlussfolgerung der Autor:innen
Faktor-XIa-Inhibitoren zeigten günstige Wirksamkeits- und Sicherheitsignale. Milvexian-Regime rangierten bei ischämischen Endpunkten höher, niedrigere Asundexian-Dosen bei Blutungseindpunkten; größere RCTs sind erforderlich.
Kernaussagen
- Milvexian rangierte bei ischämischen Endpunkten am höchsten
- Niedrigere Asundexian-Dosen rangierten günstiger bei Blutungen
- Große Unsicherheit durch breite, überlappende 95 %-CrIs
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von Yousif Kurmasha und 9 weiteren Autor:innen.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Factor XIa inhibitors are promising antithrombotic agents for secondary stroke prevention due to their potential to reduce thrombotic events while minimizing bleeding risk. However, the comparative efficacy and safety of different regimens remain uncertain in patients with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack.
Methods
A systematic search of major databases and trial registries identified randomized controlled trials evaluating factor XIa inhibitors in patients with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack receiving background antiplatelet therapy. Eligible studies compared placebo with asundexian (10 mg once daily [OD], 20 mg OD, and 50 mg OD) or milvexian (25 mg OD, 25 mg twice daily [BID], 50 mg BID, 100 mg BID, and 200 mg BID) and enrolled patients within 48-72 hours of the index event. A Bayesian random-effects network meta-analysis was performed to compare treatment strategies across dose regimens. Relative risks (RRs) with 95% credible intervals (CrIs) were estimated, and treatment ranking probabilities were assessed using the surface under the cumulative ranking curve (SUCRA). The primary outcome was ischemic stroke, while secondary outcomes included transient ischemic attack and major bleeding.
Results
Three randomized controlled trials comprising 16,255 participants were included in the analysis. Milvexian 100 mg BID demonstrated the greatest probability of reducing ischemic stroke (SUCRA 63.81), followed by milvexian 25 mg BID (SUCRA 61.72). Among asundexian regimens, 50 mg OD ranked highest (SUCRA 56.78). For transient ischemic attack, milvexian 50 mg BID demonstrated the greatest probability of reducing risk (SUCRA 69.92), followed by milvexian 25 mg OD (SUCRA 69.43). Asundexian 20 mg OD ranked highest among asundexian regimens (SUCRA 66.00). Regarding major bleeding, asundexian 20 mg OD demonstrated the highest probability of reducing bleeding risk (SUCRA 69.10), followed by asundexian 10 mg OD (SUCRA 61.76). Across outcomes, credible intervals were wide and overlapping, indicating substantial uncertainty in comparative treatment effects. Direct and indirect comparisons across the network were generally consistent, with no major evidence of inconsistency.
Conclusions
Among patients with recent non-cardioembolic ischemic stroke or high-risk transient ischemic attack, factor XIa inhibitors showed favorable efficacy and safety signals, with milvexian regimens ranking higher for ischemic outcomes and lower-dose asundexian regimens ranking more favorably for bleeding outcomes. However, substantial uncertainty remains, warranting larger randomized trials to define optimal treatment strategies.
Zitieren
APA
Kurmasha, Y., Hamzah, K. A., Alsaadany, K. R., Shahzaib, M., Tuaimah, S. R., Al-Ibraheem, A. M. T., Roshaan, M., Abdulsalam, A. M., Khlaifawi, A., & Hameed, A. A. Z. (2026). Abstract 10312: Factor XIa Inhibitors for Secondary Prevention After Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack: A Bayesian Network Meta-Analysis. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.10312
Vancouver
Kurmasha Y, Hamzah KA, Alsaadany KR, Shahzaib M, Tuaimah SR, Al-Ibraheem AMT, et al. Abstract 10312: Factor XIa Inhibitors for Secondary Prevention After Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack: A Bayesian Network Meta-Analysis. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.10312
BibTeX
@article{Kurmasha2026,
author = {Kurmasha, Yousif and Hamzah, khadeeja A and Alsaadany, Khalid Radwan and Shahzaib, Muhammad and Tuaimah, Sajjad Rasool and Al-Ibraheem, Abdullah Muataz Taha and Roshaan, Muhammad and Abdulsalam, Ameen M and Khlaifawi, Ahmed and Hameed, Al-Tuaama Abdullah Zeyad},
title = {Abstract 10312: Factor XIa Inhibitors for Secondary Prevention After Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack: A Bayesian Network Meta-Analysis},
journal = {Circulation},
year = {2026},
volume = {154},
number = {Suppl_1},
doi = {10.1161/circ.154.suppl_1.10312}
}
EUVIMED